Renaparin

DRUG3 trials

Sponsors

Corline Biomedical AB

Conditions

Delayed Graft Functionend-stage renal disease or otherwise an insufficient kidney function

Phase 1

Renaparin® in Kidney Transplantation

CompletedNCT03773211

Corline Biomedical ABDelayed Graft Function

Start: 2019-02-14End: 2020-04-21Updated: 2020-07-01

Phase 2

A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of kidney graft function in deceased-donor transplant recipients, with an additional 9-month follow-up.

WithdrawnCTIS2022-501389-23-00

Corline Biomedical ABend-stage renal disease or otherwise an insufficient kidney function

Target: 45Updated: 2023-01-18

A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of kidney graft function in deceased-donor transplant recipients, with an additional 9-month follow-up.

Not yet recruitingCTIS2022-501389-23-02

Corline Biomedical ABend-stage renal disease or otherwise an insufficient kidney function

Target: 52Updated: 2025-08-31